Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype

Leukemia

Volumn 22, Issue 8, 2008, Pages 1539-1541

  Haferlach, Claudia ^a   Dicker, F ^a   Herholz, H ^a   Schnittger, S ^a   Kern, W ^a   Haferlach, T ^a  

^a MLL MUNICH LEUKEMIA LABORATORY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD135 ANTIGEN; MIXED LINEAGE LEUKEMIA PROTEIN; NUCLEOPHOSMIN; PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ALLELE; ARTICLE; CYTOGENETICS; GENE DELETION; GENE INSERTION; GENE LOSS; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; KARYOTYPE; MISSENSE MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; NONSENSE MUTATION; PRIORITY JOURNAL; RNA SPLICING;

EID: 49349140725     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.143     Document Type: Article

References (16)

1. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-310.
2. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loucheux-Lefebvre MH et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991; 78: 1652-1657.
3. Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Lai JL, Vanrumbeke M et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol 1992; 80: 178-183.
4. Preudhomme C, Fenaux P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997; 98: 502-511.
5. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
6. Schoch C, Kern W, Kohlmann A, Hiddemann W, Schnittger S, Haferlach T. Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile. Genes Chromosomes Cancer 2005; 43: 227-238.
7. Schoch C, Haferlach T, Bursch S, Gerstner D, Schnittger S, Dugas M et al. Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: A detailed analysis of 125 cases using conventional chromosome analysis and Fluorescence in situ hybridization including 24-color FISH. Genes Chromosomes Cancer 2002; 35: 20-29.
8. ISCN. In: Mitelman F (ed). ISCN 1995, Guidelines for Cancer Cytogenetics, Supplement to: An International System for Human Cytogenetic Nomenclature. S. Karger: Basel, 1995, pp 1-110.
9. Suzuki T, Kiyoi H, Ozeki K, Tomita A, Yamaji S, Suzuki R et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood 2005; 106: 2854-2861.
10. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. J Clin Oncol 2001; 19: 1405-1413.
11. Pedersen-Bjergaard J, Christiansen DH, Desta F, Andersen MK. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2006; 20: 1943-1949.
12. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC et al Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325-4336.
13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al., on behalf of the Medical Research Council Addult and Children's Leukemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: Analysis of 1612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322-2333.
14. Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al., on behalf of the Medical Research Council Addult and Children's Leukemia Working Parties. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML 11 trial. Blood 2001; 98: 1312-1320.
15. Schoch C, Kern W, Schnittger S, Buchner T, Hiddemann W, Haferlach T. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 2004; 89: 1082-1090.
16. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, et al., for the SWOG and ECOG. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000; 96: 4075-4083.